BRSYFBrainsWay Ltd.
This is the year BrainsWay Ltd. has to prove it’s not just a clever idea in a lab — it’s a real company with real traction, real data, and real potential to change the game in neuromodulation. The next catalyst is the 7th European Conference on B, scheduled for October 15, 2026, where the company will present its advancements in neurotechnology and medical device innovation. If the conference goes well, the stock could rally to $16.14, with a bull target of $19.37 and a bear fallback of $15.06. The market is leaning slightly bullish, with a 55% probability of the bull path, but the real test is coming in December with the FDA decision on Deep TMS for depression — a decision that could push the stock to $25.83 or even $34.44 if the clinical update is strong.
The schedule
- Thu15Oct
Conference presenting advancements in neurotechnology and medical device innovation
- Wed11Nov
Quarterly earnings release with guidance on revenue and operational performance
- Sun6Dec
FDA decision on the approval of Deep TMS for treatment of depression
- Sun6Dec
Clinical trial update on Deep TMS technology
- Sun14Feb
- Wed12May
- Wed11Aug
